Anti-ACES/ AChE/ ACHE monoclonal antibody
Anti-ACES/ AChE/ ACHE antibody for FACS & in-vivo assay
Go to AChE/ACHE products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T30082-Ab-1/ GM-Tg-hg-T30082-Ab-2 | Anti-Human AChE/ACHE monoclonal antibody | Human |
GM-Tg-rg-T30082-Ab-1/ GM-Tg-rg-T30082-Ab-2 | Anti-Rat AChE/ACHE monoclonal antibody | Rat |
GM-Tg-mg-T30082-Ab-1/ GM-Tg-mg-T30082-Ab-2 | Anti-Mouse AChE/ACHE monoclonal antibody | Mouse |
GM-Tg-cynog-T30082-Ab-1/ GM-Tg-cynog-T30082-Ab-2 | Anti-Cynomolgus/ Rhesus macaque AChE/ACHE monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T30082-Ab-1/ GM-Tg-felg-T30082-Ab-2 | Anti-Feline AChE/ACHE monoclonal antibody | Feline |
GM-Tg-cang-T30082-Ab-1/ GM-Tg-cang-T30082-Ab-2 | Anti-Canine AChE/ACHE monoclonal antibody | Canine |
GM-Tg-bovg-T30082-Ab-1/ GM-Tg-bovg-T30082-Ab-2 | Anti-Bovine AChE/ACHE monoclonal antibody | Bovine |
GM-Tg-equg-T30082-Ab-1/ GM-Tg-equg-T30082-Ab-2 | Anti-Equine AChE/ACHE monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T30082-Ab-1/ GM-Tg-hg-T30082-Ab-2; GM-Tg-rg-T30082-Ab-1/ GM-Tg-rg-T30082-Ab-2; GM-Tg-mg-T30082-Ab-1/ GM-Tg-mg-T30082-Ab-2; GM-Tg-cynog-T30082-Ab-1/ GM-Tg-cynog-T30082-Ab-2; GM-Tg-felg-T30082-Ab-1/ GM-Tg-felg-T30082-Ab-2; GM-Tg-cang-T30082-Ab-1/ GM-Tg-cang-T30082-Ab-2; GM-Tg-bovg-T30082-Ab-1/ GM-Tg-bovg-T30082-Ab-2; GM-Tg-equg-T30082-Ab-1/ GM-Tg-equg-T30082-Ab-2 |
Products Name | Anti-AChE/ACHE monoclonal antibody |
Format | mab |
Target Name | AChE |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-AChE benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species ACES/ AChE/ ACHE VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLPm005042 | mouse Ache Lentivirus plasmid |
ORF Viral Vector | vGMLPm005042 | mouse Ache Lentivirus particle |
Target information
Target ID | GM-T30082 |
Target Name | AChE |
Gene ID | 43,11423,83817,713370,489828,493674,540446,100069149 |
Gene Symbol and Synonyms | ACEE,ACHE,ARACHE,N-ACHE,YT |
Uniprot Accession | P22303,P37136,O62763,P23795 |
Uniprot Entry Name | ACES_HUMAN,ACES_RAT,ACES_FELCA,ACES_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | Asthma, Metabolic, neurobehavioral deficits, OP toxicity, Stress reaction, Toxicity and mortality in estuarine fish, Alzheimer's, decrease in birth weight |
Gene Ensembl | ENSG00000087085 |
Target Classification | N/A |
The target: AChE, gene name: ACHE, also named as ACEE, ARACHE, N-ACHE, YT. Acetylcholinesterase hydrolyzes the neurotransmitter, acetylcholine at neuromuscular junctions and brain cholinergic synapses, and thus terminates signal transmission. It is also found on the red blood cell membranes, where it constitutes the Yt blood group antigen. Acetylcholinesterase exists in multiple molecular forms which possess similar catalytic properties, but differ in their oligomeric assembly and mode of cell attachment to the cell surface. It is encoded by the single ACHE gene, and the structural diversity in the gene products arises from alternative mRNA splicing, and post-translational associations of catalytic and structural subunits. The major form of acetylcholinesterase found in brain, muscle and other tissues is the hydrophilic species, which forms disulfide-linked oligomers with collagenous, or lipid-containing structural subunits. The other, alternatively spliced form, expressed primarily in the erythroid tissues, differs at the C-terminal end, and contains a cleavable hydrophobic peptide with a GPI-anchor site. It associates with the membranes through the phosphoinositide (PI) moieties added post-translationally. AChE activity may constitute a sensitive biomarker of RBC ageing in vivo, and thus, may be of aid in understanding the effects of transfusion[provided by RefSeq, Sep 2019].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.